Arrowhead Pharmaceuticals, Inc. (ARWR) income statement
ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$43.11+0.12 (+0.28%)
Close on Nov 18, 2026Market cap $6.09BP/E –Yield –
Arrowhead Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -33.8%
- Net margin
- -47.8%
- Return on equity, FY2025
- -0.5%
Financial strength
- Current ratio
- 5.90
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 19.3%
Valuation
- P/E ratio
- –
- Price to sales
- 9.10
- Price to book
- 13.08
- Dividend yield
- –
See a number that looks wrong?